Loading
Life sciences · Journal article
Annual Review of Cancer Biology · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metabolic reprogramming supports cancer behaviors including proliferation, survival, and therapeutic resistance. Compared to our understanding of these processes, little is known about the detoxification liabilities that are introduced as a byproduct of this reprogramming. Here, we review recent findings that collectively support the notion that the metabolic reprogramming of cancer cells is accompanied by increased production of potentially toxic metabolites. As a result, these cells are critically dependent on enzymatic processing or export of these metabolites. When such processes are blocked, endogenously produced metabolites can accumulate in distinct subcellular compartments to exert a variety of cytotoxic mechanisms in cancer cells such as DNA damage and ferroptosis. Toxic metabolite overloading is discussed as an emerging therapeutic strategy that carries potential advantages such as allowing tuning of toxicity via dietary control of metabolite production and exerting microenvironmental toxic effects to enhance overall efficacy in the heterogenous tumor.